TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: multitasking performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeling informed about genetic testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clarity of values
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum insulin-like growth factor-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Risk of hospitalization for worsening congestive heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Health alerts derived from sensor data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overjet relation of the anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS (rest/mobilization) at 9 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ibuprofen consumption in the first 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total AUSCAN scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global rating of disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cisapride area under the concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate surgical anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median peak sensory level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of surgical anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of drug and alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical health as it pertained to quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of OHSS
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of OHSS
Endpoint domain: Adverse events/effects
Primary endpoint: Pregnancy rates
Endpoint domain: Physiological/clinical
Primary endpoint: Overall comfort of orthoses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Arch cushioning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the receiver operating curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-observer reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum esophagitis grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy and safety of E0302
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in GERD RDQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in dyspepsia RDQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: esophageal acid exposure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of acid refluxes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: heartburn control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: SOFA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean regional tissue oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBeAg seroconversions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discussion of sex-related matters
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-recurrence survival (PRS)
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients who were emesis free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: session recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-month complete closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of dissection
Endpoint domain: Adverse events/effects
Primary endpoint: ROS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8‐isoprostane plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % FEV1 reversibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase in brain GSH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ingress of trypan blue in the aqueous aspirate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of left ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of area of infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diminished maximum hypokinesia in the central infarcted region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predialysis arterial plasma pH values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triceps skinfold thickness (TSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ejection fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of stay for admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Health state score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Height loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased tendon stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean homocysteine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of coughs
Endpoint domain: Adverse events/effects
Primary endpoint: HBsAg-positivity at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Virological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 6-minute walk test distance walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankle plantar flexor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Loss of joint space width in the index knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of > or = 20% increase in knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of head lice treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Torque Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PWL (Physical Work Load)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6mwd (6-Minute Walk Distance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abdominal visceral pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rescue analgesic treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cumulative incidence rate for AML/MDS
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence rate for any SMN
Endpoint domain: Mortality/survival
Primary endpoint: Time below therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of INR in range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major complications of thrombosis or bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: ECAR (Early Cutaneous Allergen Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LCAR (Late Cutaneous Allergen Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Formation of new dentinal microcracks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT assessed lung toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion recovered at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Functional work status recovery at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cumulative incidence of gastroduodenal ulcers >/= 3 mm
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Homeostasis model of assessment‐estimated B cell function (HOMA‐B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: neutrophil resting burst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean trough reduction in sitting diastolic blood pressure (SiDBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean trough reduction in sitting systolic blood pressure (SiSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and percentage of responders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Interval from initial dose to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Urinary oxalate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Undergoing PSA-based prostate cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HbA1c concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total β-cell response during GIP infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: time to onset of significant pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder pain and disability index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: burnout
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prevalence of total behavior problems at home
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of antisocial behavior at home
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of total behavior problems at school
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of antisocial behavior at school
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonization of Staphylococcus aureus (SA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Florbetapir PET SUVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCAM-1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Lowering of LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Increase in endothelium dependent vasodilation (EDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Enhancement of vascular distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of symptoms of the common cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of symptoms of the common cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obstruction rates in renal scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensitivity of LC-SF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of LC-SF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance with final clinical diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benefit from tamoxifen in ER-positive patients
Endpoint domain: Mortality/survival
Primary endpoint: Benefit from tamoxifen in ER-negative patients (PgR-positive group)
Endpoint domain: Mortality/survival
Primary endpoint: Comfort level of fluorexon versus fluorescein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stinging and burning effect at 1 minute
Endpoint domain: Adverse events/effects
Primary endpoint: weekly dose of i.v. iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hazard ratios for first coprimary outcome
Endpoint domain: Mortality/survival
Primary endpoint: Hazard ratios for second coprimary outcome
Endpoint domain: Mortality/survival
Primary endpoint: Severe speech impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained virological response at 24 weeks post-treatment (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency in training nurses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of microcracks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ultrasonic preparation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bone mineral content increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVLT‐II verbal memory scores for immediate recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inhibition‐switching completion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI-for-age z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Lens (IOL) decentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Lens (IOL) tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Internal tibial torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary efficacy outcome events
Endpoint domain: Mortality/survival
Primary endpoint: Principal safety outcome events
Endpoint domain: Adverse events/effects
Primary endpoint: Heart-type fatty acid-binding protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ciliary loss and epithelial abnormalities duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery (QoR-40 score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time of first anal exhaust after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to get out of bed after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood to return to work within three months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: amelioration of pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drop in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Local immediate and delayed reactions
Endpoint domain: Adverse events/effects
Primary endpoint: N(1) latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative risk of leukemia
Endpoint domain: Adverse events/effects
Primary endpoint: median TLUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of unformed stools passed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical wellness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of SSEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return of bladder and bowel functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAP-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: average deviation from the correct long-leg axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Levels of IgA and IgM C. pneumoniae antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall success rate for first intubation attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Arteriovenous passage of fluorescein dye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular safety
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic safety
Endpoint domain: Adverse events/effects
Primary endpoint: Surgeons' rating of surgical site exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Amplitude Glycemic Excursion (MAGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hourly mean blood glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin dose required to maintain euglycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Predefined learning goals achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Insulin response to OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rectal normal tissue complication probability (NTCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of definite or probable CRBSI
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in frequency of facial muscle spasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower severity score of facial muscle spasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of borborygmus
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of PEG solution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: minimal luminal diameter of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Children's glasses acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OCT strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: binary in-stent angiographic restenosis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal relative CEA decrease (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year patient/graft survival
Endpoint domain: Mortality/survival
Primary endpoint: rate of abnormal liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in wall thickness (WT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Itching mean score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in mean luteal phase VAS-Mood scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients being emesis-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sweat sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rectal temperature rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to persistent sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of nocturnal awakenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversion of sensory-motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aqueous humor flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes in treatment with neuroleptic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referrals to community psychiatric nurses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-, 2-, 3-, and 5-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Self-care
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PANSS positive subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression‐Severity (CGI‐S) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes